Dear Ms Adina-Ioana Vălean,

I refer to your letter of 19 October 2017 regarding the Commission Delegated Regulation setting out scientific criteria for the determination of endocrine disrupting properties pursuant to Regulation (EU) No 528/2012 on the placing on the market of Biocidal Products, which is currently under scrutiny by the European Parliament.

I am pleased to confirm the explanation already provided at the meeting of the Committee on 11 October that, in accordance with Article 19(4)(d) of Regulation (EU) No 528/2012, any biocidal product that has endocrine-disrupting properties cannot be authorised for making available on the market for use by the general public. Since in Article 19(4)(d) there is no reference as to whether the endocrine disrupting property is with regard to target organisms or non-target organisms, biocidal products containing active substances with an intended endocrine disrupting effect on target organisms are covered by this Article and therefore the ban of the sale to the general public applies to them.

Please allow me to stress that the criteria adopted by the European Commission for the determination of endocrine disrupting properties are protective of human health and the environment as they are based on the widely agreed World Health Organisation's definition of an endocrine disruptor, and will allow identifying known and presumed substances with endocrine disrupting properties.
The entry into force of the criteria will be a significant step forward compared to the currently applicable interim criteria with respect to a better protection of human health and the environment.

I hope I can count also on the support of the European Parliament in this endeavour.

Yours sincerely,